Renaissance

Renaissance is a specialized CDMO and a pure-play leader in nasal spray and sterile injectable contract manufacturing. Founded in 2020 but with roots dating to 1979, it operates from a large facility in Lakewood, New Jersey, offering end-to-end services from formulation development through commercial production. In late 2025, the company was acquired by LTS Lohmann Therapie-Systeme AG, significantly expanding its global reach and capabilities within a larger pharmaceutical technology group. Its core value proposition is deep expertise in nasal drug delivery, supported by state-of-the-art spray testing and multiple GMP manufacturing suites.

Integrated CDMO platform for nasal spray and sterile injectable dosage forms, featuring specialized spray characterization, formulation development, aseptic fill-finish, and full analytical testing services.

Renaissance competes in the specialized CDMO segment for nasal and sterile injectables against other pure-play firms and larger, diversified CDMOs. Its deep nasal spray expertise and 'one-stop-shop' model are differentiators. The acquisition by LTS now positions it against other global, full-service drug delivery CDMO giants.